Press Release: Novartis showcases significant -2-

forward-looking statements contained in this press release as a result of new information, future events or otherwise.

About Novartis

Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people's lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach nearly 300 million people worldwide.

Reimagine medicine with us: Visit us at https://www.novartis.com/ https://www.novartis.com and connect with us on https://www.linkedin.com/company/novartis/ LinkedIn, https://www.facebook.com/novartis/ Facebook, https://twitter.com/Novartis X/Twitter and https://instagram.com/novartis?igshid=MzRlODBiNWFlZA==__;!!N3hqHg43uw!pjp8z253J5NjaOYrW65UbAAlHeHRdQ-w0m4ezZxEQEl0ptafXN2M99VRIk39pf49PAc8NbK93Pxp3uaSBQkAf8oEnzWXG8Sk$ Instagram.

References

1. Novartis. Data on file.

2. Morand E, et al. Biomarker Data From an Open-Label, Phase 1/2 Study for

YTB323 (Rapcabtagene Autoleucel, a Rapidly Manufactured CD19 CAR-T

Therapy) Suggest Reset of the B Cell Compartment in Severe Refractory

SLE. Abstract presented at ACR Convergence 2025. Accessed September 19,

2025.

https://acrabstracts.org/abstract/biomarker-data-from-an-open-label-phase-1-2-study-for-ytb323-rapcabtagene-autoleucel-a-rapidly-manufactured-cd19-car-t-therapy-suggest-reset-of-the-b-cell-compartment-in-severe-refractory-sle/

3. Armstrong A, et al. Comparison of Incidence of Psoriatic Arthritis in

Patients With Psoriasis Treated With Interleukin-17 Inhibitors vs

Interleukin-23 Inhibitors, Interleukin-12/23 Inhibitors, and Tumor

Necrosis Factor Inhibitors in Real-World Practice: A Retrospective Study.

Abstract presented at ACR Convergence 2025. Accessed September 19, 2025.

https://acrabstracts.org/abstract/comparison-of-incidence-of-psoriatic-arthritis-in-patients-with-psoriasis-treated-with-interleukin-17-inhibitors-vs-interleukin-23-inhibitors-interleukin-12-23-inhibitors-and-tumor-necrosis-factor-i/

4. Dorner T, et al. Safety and Efficacy of ianalumab in patients with

Sjogren's disease: 52-week results from a randomized, placebo-controlled,

phase 2b dose-ranging study. Arthritis and Rheumatology. 2025;

77(5):560-570

5. Negrini S, et al. Sjogren's syndrome: a systemic autoimmune disease, Clin

Exp Med. 2022; 22(1): 9-25

6. National Academies of Sciences, Engineering, and Medicine; Health and

Medicine Division; Board on Health Care Services; Committee on Selected

Immune Disorders and Disability. Sjogren's Disease/Syndrome. Accessed

September 11, 2025. https://www.ncbi.nlm.nih.gov/books/NBK584486/

7. ClinicalTrials.gov NCT05798117

https://clinicaltrials.gov/study/NCT05798117 [Last accessed: September

2025]

8. ClinicalTrials.gov NCT06665256

https://clinicaltrials.gov/study/NCT06665256?cond=Inflammatory%20Myopathies&viewType=Table&rank=5

[Last accessed: September 2025]

9. ClinicalTrials.gov NCT06655896

https://clinicaltrials.gov/study/NCT06655896 [Last accessed: September

2025]

# # #

Novartis Media Relations

E-mail: media.relations@novartis.com

Novartis Investor Relations

Central investor relations line: +41 61 324 7944

E-mail: investor.relations@novartis.com

(END) Dow Jones Newswires

October 25, 2025 10:59 ET (14:59 GMT)